ASHG News

 You must be a member to access this page. Log in Become a Member If you believe you have a membership and are unable to log in contact membership@ashg.org Read More

In 2018, the U.S. Food and Drug Administration (FDA) invited comments on its intention to exempt a list of class II devices from premarket notification requirements, including tests assessing genetic health risks. ASHG responded to this request for comment by outlining its support for regulation that brings scientifically valid, evidence-based tests to market, and expressing... Read More

I am delighted to announce that ASHG’s statement on germline genome editing was published today in The American Journal of Human Genetics. This statement, written by a workgroup co-led by Kelly Ormond and Doug Mortlock and approved by ASHG’s Board of Directors, gives the Society’s perspective on the use of CRISPR/Cas9 or other similar tools... Read More

In 2017, ASHG and 10 international organizations published a position statement on human germline genome editing in The American Journal of Human Genetics. The statement recommended against genome editing culminating in human pregnancy, supported publicly funded in vitro research into its potential clinical applications, and outlined scientific and societal steps necessary before implementation of such... Read More

ASHG supports DNA profiling as a law enforcement tool to identify criminals and exonerate the innocent. The Society believes, however, that the use of DNA in those contexts must respect the public’s right to privacy and that DNA collection should be limited to those convicted of or reasonably suspected of having committed a serious crime.... Read More